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Abstract
Aims/Background—This study was under­
taken to confirm the association between 
diffuse retinal pigment epitheliopathy 
(DRPE) and systemic corticosteroid 
therapy. This finding can be of help in  
determining an aetiological factor in  
DRPE and associated diseases. Corti­
costeroids may contribute to the develop­
ment o f leakage in the presence o f a retinal 
pigment epitheliopathy or central serous 
chorioretinopathy.
Methods—Cases o f DRPE were collected 
from the files of members of the European 
Fluorescein Angiography Club. There 
were 34 who developed their ophthalmic 
symptoms while being treated with corti­
costeroids
Results—DRPE developed in 34 patients 
from 10 European eye clinics during 
system ic treatm ent with corticosteroids. 
Thirteen patients were treated with 
corticosteroids after allotransplantation, 
21 other patients developed ocular 
symptoms while treated with steroids for 
serious system ic disorders. Symptoms 
occurred in some patients when the 
daily corticosteroid dosage was elevated, 
and the visual complaints am eliorated  
or even disappeared som etim es on 
discontinuation of the corticosteroid  
therapy.
Conclusion—Corticosteroids can damage 
the retinal pigment epithelial barrier and 
predispose a patient to serous retinal 
detachment, whereas psychological stress 
may play a role in the development o f  
central serous chorioretinopathy. A 
decrease o f the daily corticosteroid dosage 
may help to diminish the visual 
sym ptom s.
(.B rJ  Ophthalmol 1995; 79: 922-925)
Diffuse retinal pigment epitheliopathy 
(DRPE) or chronic central serous retinopathy 
resembles both acute central serous chorio­
retinopathy and pigment epithelial detach­
ment, but can be differentiated by the 
following characteristic features: widespread 
distribution of small pigment epithelial detach­
ments, only a few funduscopically pigment 
epithelial alterations in the presence of more 
extensive pigmentary changes with variable 
leakage on the fluorescein angiogram, chronic 
course with exacerbations and remissions, 
often bilateral in appearance, fair visual out­
come in most patients usually with remaining 
disturbance of colour vision and troublesome 
metamorphopsia.1 2
Differential diagnosis can only be made 
fluorographically, whereas borderline cases 
do occur. The differences between diffuse 
retinal pigment epitheliopathy on the one 
hand and pigment epithelial detachment and 
acute central serous chorioretinopathy on the 
other are quantitative rather than qualitative. 
The major distinction between chronic and 
acute disease is the fact that chronic disease 
has widespread pigment epithelial changes 
without overt detachment in most cases, 
whereas in acute disease there is focal pig­
ment epithelial abnormality and marked 
detachment.
The disorders may be asymptomatic if 
the fovea is not involved or if the disease 
occurs in the non-dominant eye. In most 
patients major visual symptoms resolve after 
a few months, but small funduscopically 
visible pigment epithelial alterations usually 
remain as well as complaints of meta­
morphopsia, micropsia, colour vision 
changes, and/or darkening of the central 
visual field. Central serous chorioretinopathy 
following systemic corticosteroids has been 
recorded previously.3 Several authors 
reported the occurrence of central serous 
chorioretinopathy or serous retinal detach­
ment after organ transplantation, when stress 
factors in combination with immunosuppres­
sive therapy are present and may play a role in 
the development of the ocular symptoms.4 6 
These findings were discussed within the 
European Fluorescence Angiography Club 
together with similar observations by one of 
us in patients with systemic disorders and 
therapy with corticosteroids. We collected as 
many patients as possible with these oph­
thalmic findings complicating systemic corti­
costeroid treatment.
Patients and methods
The members of the European Fluorescein 
Angiography Club agreed to collect from their 
clinical files and photographic and fluoro- 
angiographic documentation patients with the 
diagnosis of DRPE, who developed their 
ophthalmic symptoms while being treated 
with corticosteroids: 10 Belgian patients, 18 
Dutch patients, five French patients, and 
one German patient could be diagnosed as 
such.
The diagnosis was made according to 
the following criteria, based on the clinical 
manifestations as described by Zweng and 
Little: widespread distribution of small 
pigment epithelial detachments, extensive 
pigmentary changes, chronic course with 
exacerbations and remissions.1
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Table 1 Survey of the patients who developed diffuse retinal pigment epitheliopathy or 
chronic central serous chorioretinopathy during corticosteroid therapy after transplantation
Eye clinic Sex
Age
(years)
Transplanted
organ
Daily
dosage
(mg)
Duration 
of therapy 
( months)
A  niihypertensive 
treatment
1 Brussels M 38 Kidney 12’5 4 +
2 F 35 Kidney 10 2 +
3 M 44 Kidney 10 10 +
4 M 37 Kidney 12*5 l/4
5 M 37 Kidney 10 2
6 Leuven M 49 Kidney 8 12 ■+
7 Paris F 52 Kidney 15 84 ■+
8 Albi M ?« Kidney ? 24
9 Rotterdam F 32 Kidney 10 108 +
10 M 43 Kidney 10 4
11 M 42 Kidney 10 6
12 M 48 liv e r 15 3
13 M 48 H eart 15 11
Total 10 + 3 «  13 patients
b
Results
Thirteen patients developed DRPE or chronic 
central serous chorioretinopathy during 
corticosteroid therapy after allotransplanta­
tion (Table 1), and 21 patients while being 
treated with prednisone for systemic diseases 
(Table 2). Several patients developed visual 
complaints when the daily corticosteroid 
dosage was elevated (cases 1, 7, 12, and 20; 
Table 2; Figs 1-5). In three patients recovery 
accompanied a reduction in steroid treatment 
to a low level (cases 7, 12, and 20; Table 2, 
Figs 3-5). The multifocal nature of the chorio­
retinopathy is evident from the figures shown. 
All transplanted patients -  except the only 
female kidney transplant recipient -  were 
treated with azathioprine (Imuran) and also 
cyclosporin. Out of the 13 transplanted 
patients seven were also treated for hyperten­
sion (Table 1), whereas five patients of the 
21 with systemic diseases needed antihyper­
tensive treatment in combination with the 
corticosteroids (Table 2).
The ages of the transplanted patients varied 
from 32 to 52 years (mean 40 years), those of 
the patients with systemic disorders from 37 to 
68 years (mean 52 years) (see Table 3). 
Nineteen patients developed DRPE or chronic 
central serous chorioretinopathy in one eye, 
and 15 patients had pigmentary epithelial 
changes in both eyes.
Two eyes within the transplanted group and 
four eyes within the other group of patients 
reached a final visual acuity of 0-1 or less 
(Table 3).
Discussion
Diffuse retinal pigment epitheliopathy or 
chronic central serous chorioretinopathy 
complicating systemic corticosteroid treatment 
was found in the patients collected by the 
members of the European Fluorescein 
Angiography Club. Since the cases have been 
derived from a very large European popula-
M  An J L  A ,
tion, we cannot exclude the fact that the find­
ing is by chance alone.
Several patients however developed visual 
complaints when the daily corticosteroid 
dosage was elevated and recovery accom­
panied a reduction in steroid treatment to a 
low level, as could be confirmed by the obser­
vations in some of our patients (see cases 1, 7, 
12, and 20; Table 2). These findings suggest a 
possible relation between DRPE or chronic 
central serous chorioretinopathy and treatment 
with systemic corticosteroids.
The fact that the form of central serous 
chorioretinopathy is different from that seen 
most commonly -  namely, acute disease, may 
reinforce the argument that there is a causal 
relation between the steroids and the fundus 
changes. Three out of 60 patients with endo­
genous Cushing’s syndrome had one or more 
episodes of central serous chorioretinopathy 
while plasma cortisol levels were high.7 
Furthermore, the disease has been modelled 
experimentally in primates using prolonged 
infusions of intravenous noradrenaline.8 q Two 
of our patients were treated with oral pred­
nisone because of symptoms of a neuritis retro- 
bulbaris and also developed a DRPE (Table 2). 
Similar findings have been described by other 
authors, and in one patient the central serous 
chorioretinopathy recurred three times during 
three separate courses of treatment.3
Central serous chorioretinopathy is a 
recognised complication of pregnancy.1013 A 
possible effect of endogenous corticosteroids
Table 2 Survey o f the patients who developed diffuse retinal pigment 
chorioretinopathy while being treated with corticosteroids for systemic diseases
or chronic central serous
Eye clinic Sex
Age
(years)
Indication for 
therapy
Daitv
dosage
(mg)
Duration 
of therapy 
(months)
A  niihypertensive 
treatment
1 Brussels M 65 Pemphigoid 8-32 5
2 Leuven M 37 Besnier-Boeck 8-64 12
3 M 37 Neuritis 40 1
4 M 52 Renal failure, haemodialysis ? ?
5 M 38 Bechterew, colitis ulcerosa 90-180 ?«
6 Leiden M 40 Asthma 7• 1
7 M 42 Rheumatoid ? 1
8 Paris F 39 Colitis ulcerosa 10 120
9 M 52 Idiopathic thrombopenia 20 96
10 M 47 Lupus erythematodes 60 5
11 Rotterdam M 68 Arteritis 60 0 • 5 H Ji'
12 M 46 Addison 50 60 384 - t "
13 M 45 Myositis 40-60 1
14 M 38 Colitis ulcerosa 20-75 6
15 M 45 Asthma ? 1
16 F 37 Asthma 20-40 2
17 F 38 Asthma 40 1
18 M 40 Rheumatoid ? ?
19 M 45 Neuritis 60 5
20 Nijmegen F 62 Asthma 25 120
21 Groningen M 39 Asthma 5 120
Total 21 patients
924 Polak, Baarsma, Snyers
methylprednisolone a day in the right eye of a female patient
j Table 2). Visual acuity 
an episode with exacerbation, while the
zuas increased.
Figure 2 Increasing leakage during the late phase o f the 
fluorogram (case 1, Table 2) of the right eye in the same 
patient as in Figure L
Figure 5 Symptoms of pigment epithelial damage and 
leakage in the left eye (case 20y Table 2) of the same 
patient as in Figure 4. When the daily prednisone dosage 
was
fluorescein in both eyes, while the visual symptoms 
ameliorated.
Table 3 Summary of the findings in 34 patients with 
diffuse retinal pigment epitheliopathy or chronic central 
serous c,
y m
Diffuse retinal pigment epitheliopathy (DRPE) during
Figure 3 Multiple areas of retinal detachment in the right 
eye (case 12, Table 2) of a male patient with Addison 's 
disease. Ophthalmic symptoms developed while the patient 
treated himself with 120 mg prednisone a day. The 
fluorographic visible leakage disappeared when the 
prednisone dosage zvas reduced to 60 mg a day.
European FAN club:
13 Patients ( 10 male, 3 female)
Ages varying from 32-52 years (mean 40) 
Occurrence 1 week-9 years alter transplantation 
Unilateral symptoms in 8 patients 
Bilateral symptoms in 5 patients 
Argon laser treatment in 4 eyes 
Final visual acuity <0-1 in 2 eyes 
DRPE during corticosteroid therapy without previous 
transplantation within the European FAN club:
21 Patients (17 male, 4 female)
Ages varying from 37-68 years (mean 52) 
Unilateral symptoms in 11 patients 
Bilateral symptoms in 10 patients 
Argon laser treatment in 4 eyes 
Final visual acuity <0*1 in 4 eyes
during pregnancy on the posterior blood- 
ocular barrier has been suggested, since two 
attacks of central serous chorioretinopathy 
developed in one patient during two successive 
pregnancies and even four attacks in another 
patient during four pregnancies, each attack 
resolving spontaneously after delivery or 
spontaneous abortion.1013 The multifocal 
nature of the leakage, as has been found in our 
patients, was indeed also seen in pregnancy.
The possible aetiological role of hyper­
activity of the adrenomedullary system is sus­
tained by the development of central serous 
chorioretinopathy especially in patients with a 
type A behaviour pattern, associated with 
increased catecholamine secretion.14 There is 
doubtless a strong genetic factor which decrees 
that some subjects respond to either pleasur­
able or unpleasant stress in an inappropriate 
way, thus displaying pathological anxiety or
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stress.15 DRPE and central serous chorio- (Tables 1 and 2). In many diseases the steroid
retinopathy seem also to be genetically related, treatment may be life saving and the possible
since in one family one brother had a DRPE, susceptibility of the patient to central serous
one sister had a typical central serous chorio- chorioretinopathy does not represent a contra-
retinopathy and the other brother had DRPE indication for therapy.
in one eye with recurrent central serous chorio­
retinopathy in the other eye.2 Furthermore,
Corticosteroid therapy has been widely 
used for the treatment of central serous
central serous chorioretinopathy has also been chorioretinopathy and associated disorders
described in a pair of identical twins.16 The findings in our patients in contrast make
Until now several authors have suggested clear that caution should be exercised when 
that corticosteroids can damage the retinal corticosteroids are used in certain patients sus-
seases: cortico-pigment epithelial barrier and predispose a ceptible to 
patient to serous retinal detachment, but con- steroids may give rise to symptoms of DRPE or
vincing evidence that any of 
directly contributes to the development
chronic
instead of diminishing them, whereas recovery
central serous chorioretinopathy and associ- may occur when the daily dosage is lowered.
This paper is the result of a collaboration within the European 
Fluorescein Angiography Club.
The authors wish to thank the following members of the 
European Fluorescein Angiography Club, who kindly agreed to 
send their clinical data; P Amalric (Albi, France); J A Bernard 
(Paris, France); A Bird* A M Hamilton, J Shilling (London, 
Great Britain); G Chaîne (Paris, France); G Coscas and G 
Soubrane (Creteil, France); A F Deutman (Nijmegen, the 
Netherlands); J Hooymans and Z Timmermans (Groningen, 
the Netherlands); J J de Lacy and H A Priem (Gent, Belgium); 
A Leys (Leuven, Belgium); J A Oosterhuis and R Bors je 
(Leiden, the Netherlands); C Verougstraete 
Belgium); and A Wessing (Essen, Germany).
one
was lacking so far.3 1718 
Psychological stress may have played a key 
role in the development of a DRPE or chronic 
central serous chorioretinopathy in our 
patients, but the simultaneous administration 
of prednisone may certainly have influenced 
the final visual outcome, especially since the 
ophthalmic symptoms decreased in some 
patients when the daily prednisone dosage was 
diminished.
Each of our transplanted patients -  except
also used other immunosuppressive 
agents such as azothioprine and cyclosporin, 
whereas some other drugs were used as well by 
the other patients treated for systemic dis­
orders. None of these drugs, however, is 
known so far to be involved in the development 
of chorioretinal changes.
The findings in our patients differ from the 
leopard-like geographical areas of disruption 
and coarse clumping of the pigment epithelium 
in the posterior fundi, observed in some post­
transplant patients.19 Localised choroidal 
intravascular coagulation is the suspected but 
unproved cause of the pigment epithelial 
changes in those patients. However, choroidal 
vascular changes have been described before 
in haemodialysis and kidney transplanta 
tion patients, which changes may promote 
the development of pigment epithelium
Pigment epithelial alterations are
¿seis,
1<■) 2 0
seen in some patients with hypertension, and 
the fact that 12 of our patients were hyper­
tensive might have promoted the development 
of a DRPE or chronic central serous retino­
pathy. In these 12 patients the use of cortico­
steroids also may have worsened their 
hypertension, so the pigment epithelial altera­
tions in these patients can be directly as well as 
indirectly attributed to the corticosteroid treat­
ment.
Both ß blocking agents propranolol and 
atenolol modify type A behaviour, and the use 
of these drugs has been mentioned as a useful 
therapy in patients with a central serous 
chorioretinopathy.15 Five of the 12 patients 
who were treated with antihypertensives did 
actually get betalytic agents as well as cortico­
steroids when they developed a DRPE or 
chronic central serous chorioretinopathy
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